Hear why Science Corp CEO Max Hodak says the screen era is ending at TechCrunch Disrupt 2026

Brain-computer interfaces are starting to restore human capabilities, not just augment them.

Science Corporation CEO Max Hodak will speak at TechCrunch Disrupt 2026 about the end of the screen era and the rise of new human-computer interfaces. Hodak, who co-founded Neuralink, is now focused on biohybrid brain-computer interfaces at Science Corp. The company aims to develop technologies that adapt to users through brain-computer interactions, moving beyond traditional screens. Science Corp has already achieved success with its PRIMA implant, which has restored sight for individuals with severe vision loss. The company has raised $230 million in Series C funding at a $1.5 billion valuation. Hodak's presentation will explore how these advanced neural engineering interfaces could create new ways of engaging with machines and address various medical conditions.

Science Corp's advancements in biohybrid brain-computer interfaces, particularly with the PRIMA implant restoring sight, indicate a tangible shift towards direct neural interaction for functional restoration. This moves beyond the augmentation often discussed with BCIs, suggesting a future where severe disabilities might be overcome through technological integration with the brain. The company's success and significant funding underscore a growing market interest in technologies that offer profound improvements in human capability, potentially redefining assistive technologies and healthcare.

The focus on neural engineering and biohybrid interfaces signals a potential paradigm shift away from conventional display-based computing. Hodak's perspective, rooted in his experience with Neuralink and now Science Corp, suggests that the next wave of human-machine interaction will be more intuitive and integrated, addressing needs in vision, cognition, and mobility. This could impact how we design user experiences and develop applications, prioritizing direct neural input and feedback over screen-based modalities, and opening new avenues for therapeutic and functional technologies.